Clinical Trial Update: Phase 1b Study to Assess Safety, Tolerability, and Pharmacokinetics of ARCT-810 in Stable Adult Subjects With Ornithine Transcarbamylase Deficiency [Phase 1]

View source ↗

Summary

This update reports completion of a Phase 1b study evaluating safety, tolerability, and pharmacokinetics of ARCT-810 in adults with ornithine transcarbamylase d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ornithine Transcarbamylase Deficiency

Drugs mentioned

• ARCT-810

Snippet

Sponsor: Arcturus Therapeutics, Inc. | Conditions: Ornithine Transcarbamylase Deficiency | Phase 1 | Status: COMPLETED